Executive Director Dr. Tido von Schoen-Angerer, calls for innovative funding mechanisms for global health in the Huffington Post. read more
Inauguration of the European Parliament Working Group on Innovation & Access in Brussels read more
U.S. health care legislation could limit access read more
MSF responds to World Health Organisation’s new HIV treatment guidelines read more
MSF sends letter to EU Ministers of Health regarding antibiotic resistance read more
MSF Access Campaign signs joint declaration on the threat of EU trade policy on accessibility to essential medicines read more
World Food Summit fails to address childhood malnutrition read more
MSF leads WTO workshop on medicine detainment by customs... read more
 |
 |
|
 |
Below is a list of the companies that produce the antiretrovirals we need in the patent pool.
Click on each company to see which drugs they produce and why we need them for the pool
Abbott Laboratories
Boehringer Ingelheim
Bristol-Myers Squibb
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson/Tibotec Pharmaceuticals
Merck & Co
Pfizer Inc.
Sequoia Pharmaceuticals Inc.
Missing ARVs for HIV/AIDS treatment in 2009: Unitaid Patent Pool Briefing 
HIV/AIDS treatment in developing countries: the battle for long-term survival has just begun
Untangling the Web of antiretroviral price reductions - Upcoming 12th Edition Pre-publication price analysis July 2009
MSF Clinical Officer Olesi Ellemani Pasulani's reflections on AIDS treatment in Malawi
Living with MDR TB: 'Expert Client' Nonkululeko Mamba's Story
MDR TB Treatment in Cambodia: A Catalyst for Change
